{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T10:11:52Z","timestamp":1755598312789},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,6]]},"DOI":"10.7759\/cureus.51757","type":"journal-article","created":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T18:25:42Z","timestamp":1704565542000},"source":"Crossref","is-referenced-by-count":1,"title":["Abiraterone-Associated Mineralocorticoid Excess: A Case Report"],"prefix":"10.7759","author":[{"given":"Saeed K","family":"Shaffi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raja","family":"Ravender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandra Kumar Mallick","family":"Kodavanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoocher","family":"Soleimani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono JS","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, et al.. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011, 364:1995-2005. 10.1056\/NEJMoa1014618","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi K","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, et al.. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017, 377:352-60. 10.1056\/NEJMoa1704174","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2189","article-title":"Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer","volume":"97","author":"Attard G","year":"2012","unstructured":"Attard G, Reid AH, Auchus RJ, et al.. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab. 2012, 97:507-16. 10.1210\/jc.2011-2189","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02891-y","article-title":"High-dose dexamethasone suppression test is inferior to pituitary dynamic enhanced MRI in the differential diagnosis of ACTH-dependent Cushing's syndrome","volume":"75","author":"Shi X","year":"2022","unstructured":"Shi X, Du T, Zhu D, et al.. High-dose dexamethasone suppression test is inferior to pituitary dynamic enhanced MRI in the differential diagnosis of ACTH-dependent Cushing's syndrome. Endocrine. 2022, 75:516-24. 10.1007\/s12020-021-02891-y","journal-title":"Endocrine"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard G","year":"2008","unstructured":"Attard G, Reid AH, Yap TA, et al.. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008, 26:4563-71. 10.1200\/JCO.2007.15.9749","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.9259","article-title":"Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer","volume":"28","author":"Danila DC","year":"2010","unstructured":"Danila DC, Morris MJ, de Bono JS, et al.. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010, 28:1496-501. 10.1200\/JCO.2009.25.9259","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3980","article-title":"Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100","volume":"72","author":"Richards J","year":"2012","unstructured":"Richards J, Lim AC, Hay CW, et al.. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 2012, 72:2176-82. 10.1158\/0008-5472.CAN-11-3980","journal-title":"Cancer Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/2042018810380214","article-title":"Replication of cortisol circadian rhythm: new advances in hydrocortisone replacement therapy","volume":"1","author":"Chan S","year":"2010","unstructured":"Chan S, Debono M. Replication of cortisol circadian rhythm: new advances in hydrocortisone replacement therapy. Ther Adv Endocrinol Metab. 2010, 1:129-38. 10.1177\/2042018810380214","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2013.00012","article-title":"Pharmacogenomics of cytochrome P450 3A4: recent progress toward the \"missing heritability\" problem","volume":"4","author":"Klein K","year":"2013","unstructured":"Klein K, Zanger UM. Pharmacogenomics of cytochrome P450 3A4: recent progress toward the \"missing heritability\" problem. Front Genet. 2013, 4:12. 10.3389\/fgene.2013.00012","journal-title":"Front Genet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000477547","article-title":"Amiloride is effective in the management of abiraterone-induced mineralocorticoid excess syndrome without interfering with its antineoplastic activity","volume":"100","author":"Bedussi F","year":"2017","unstructured":"Bedussi F, Galli D, Fragni M, et al.. Amiloride is effective in the management of abiraterone-induced mineralocorticoid excess syndrome without interfering with its antineoplastic activity. Pharmacology. 2017, 100:261-8. 10.1159\/000477547","journal-title":"Pharmacology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/176267-abiraterone-associated-mineralocorticoid-excess-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:14:49Z","timestamp":1707509689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/176267-abiraterone-associated-mineralocorticoid-excess-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,6]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.51757","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,6]]}}}